Biogen Inc. received a big boost on Wednesday after U.S. Food and Drug Administration regulators appeared to give a positive assessment of the company’s experimental Alzheimer’s disease drug, sending shares up 44%.
The biotech giant is at a crossroads as it seeks regulatory approval for its potential blockbuster Alzheimer’s drug aducanumab, while facing down generic competition to its biggest-selling treatment.
Soon…
This post first appeared on wsj.com
